Human Circovirus in Patients with Hepatitis, Hong Kong

Shusheng Wu,¹ Cyril Chik-Yan Yip,¹ Jianwen Situ,¹ Zhiyu Li, Stanley Siu-Fung Ho, Jianpiao Cai, Jane Hau-Ching Poon, Nicholas Foo-Siong Chew, Jonathan Daniel Ip, Tom Wai-Hin Chung, Kelvin Hei-Yeung Chiu, Anna Jinxia Zhang, Estie Hon-Kiu Shun, James Yiu-Hung Tsoi, Jade Lee-Lee Teng, David Christopher Lung, Kelvin Kai-Wang To Vincent Chi-Chung Cheng, Irene Oi-Lin Ng, Kwok-Yung Yuen, Siddharth Sridhar

Circovirus human is a new viral species that includes the human circovirus (HCirV), which has been linked to hepatitis in immunocompromised persons. We investigated prevalence of HCirV infection in 278 patients with hepatitis and 184 asymptomatic persons using real-time PCR and sequencing assays. HCirV viremia and sequences were found in 8 (2.9%) hepatitis patients and no asymptomatic patients. Alternate causes of hepatitis (hepatitis E and cholangitis) were clearly identifiable in 2 HCirV-infected patients. HCirV could not be ruled out as a contributor to hepatitis in the remaining 6 patients, 4 of whom were immunocompromised. Persistent infections were documented in 3 patients, but only 1 had relapsing hepatitis. One HCirV patient displayed symptoms of an infectious mononucleosis-like syndrome. Isolates clustered with known HCirV strains from France and China. HCirV-derived virus-like particles bound to PLC/PRF/5 and Hep-G2 human hepatoma cells but not to lung epithelial cells, indicating hepatic tropism.

Hepatitis is a common entity; severity can range from subclinical biochemical transaminitis to acute liver failure. Common etiologies of hepatitis include viral infections, adverse drug reactions, alcohol, autoimmune disorders, metabolic diseases, and biliary pathologies. However, unexplained hepatitis is still frequently encountered in clinical practice. Studies in a variety of practice settings estimate

Author affiliations: The University of Hong Kong, Hong Kong, China (S. Wu, C.C.-Y. Yip, J. Situ, Z. Li, S.S.-F. Ho, J. Cai, J.H.-C. Poon, N.F.-S. Chew, J.D. Ip, A.J. Zhang, J.Y.-H. Tsoi, J.L.-L. Teng, K.K.-W. To, V.C.-C. Cheng, I.O.-L. Ng, K.-Y. Yuen, S. Sridhar); Queen Mary Hospital, Hong Kong (T.W.-H. Chung, K.H.-Y. Chiu, V.C.-C. Cheng); Queen Elizabeth Hospital, Hong Kong (D.C. Lung); Hong Kong Children's Hospital, Hong Kong (D.C. Lung); Centre for Virology, Vaccinology and Therapeutics, Hong Kong (E.H.-K. Shun, K.K.-W. To, K.Y. Yuen) that 11%–35% of acute liver failure cases lack a clear etiology (1). This proportion is higher in patients with mild hepatitis, for whom exhaustive laboratory investigations are usually not performed. Therefore, conceivably, some causes of infectious hepatitis remain unknown. A striking example of this possibility was the recent multinational outbreak of pediatric hepatitis for which the best current hypothesis is a co-infection of adeno-associated virus 2 and adenovirus type 41 in children with genetic predispositions (2). Another example is rat hepatitis E virus, previously disregarded as a human pathogen but now identified as an endemic hepatitis agent in China and Spain (3–5).

Circovirus human is a recently discovered species of the family Circoviridae independently reported in France and China (6-8). This species includes human circovirus (HCirV). In China, HCirV was first reported in an intravenous drug user with HIV infection (6). A follow-up study identified a second HCirV patient, also an intravenous drug user with HIV and hepatitis C virus (HCV) co-infection (9). Sparse clinical details were available for those 2 patients. Around the same time, researchers in France using metagenomic nextgeneration sequencing identified HCirV infection in a heart-lung transplant recipient with unexplained hepatitis (7). HCirV peripheral blood virus loads correlated with derangements in liver function tests (LFTs). Those researchers also demonstrated HCirV mRNA in liver tissue by in situ hybridization indicating virus tropism for hepatocytes (7).

In this study, we evaluated the role of HCirV as a cause of viral hepatitis by comparing HCirV infection prevalence in hepatitis cases and asymptomatic controls. We described the clinical profiles and genomic epidemiology of HCirV infection cases. Finally, we

DOI: https://doi.org/10.3201/eid3012.241114

¹These authors contributed equally to this article.

expressed HCirV virus-like particles (VLPs) to probe binding of HCirV to human hepatic cell lines.

Materials and Methods

Study Setting, Patient Specimens, and Animal Samples This retrospective observational study was conducted at the Queen Mary Hospital (QMH) Department of Microbiology in Hong Kong, China. The study was approved by the Institutional Review Board of the University of Hong Kong, China/Hospital Authority Hong Kong, China West Cluster (UW 23-330). The QMH microbiology laboratory provides viral hepatitis diagnostic services to acute hospitals and transplant services across Hong Kong. We retrieved plasma or serum samples from patients sent to the laboratory for diagnostic evaluation of viral hepatitis (hepatitis cases) during October 1, 2022-November 15, 2023. We assigned patients to the hepatitis cases group if alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or bilirubin were elevated above respective reference ranges (Appendix Table 1, https://wwwnc.cdc.gov/ EID/article/30/12/24-1114-App1.pdf). We excluded persons with isolated elevated ALP if their gammaglutamyl transpeptidase levels were within reference ranges (indicating extrahepatic source). Similarly, we excluded cases with isolated unconjugated hyperbilirubinemia. Archived plasma or serum samples from persons with unremarkable LFTs formed a control group; blood samples from those persons were sent to the QMH microbiology laboratory for organ donation evaluation or cytomegalovirus (CMV) reactivation monitoring. We retrieved patient clinical notes, imaging findings, and diagnostic test results from electronic patient records. As described in our previous study (5), we defined patients as immunosuppressed if they met any of the following criteria at time of blood taking: active hematological malignancy, history of solid organ or hematopoietic stem cell transplantation, receiving disease modidrugs/marrow-suppressive antirheumatic fying chemotherapy/steroids (>0.5 mg/kg/d prednisolone-equivalent for ≥ 1 mo), or living with HIV infection with CD4 T-lymphocyte counts <200 cells/mm³.

HCirV PCR screening was conducted by staff blinded to group assignment. Patients were defined as infected with HCirV if they fulfilled both of the following criteria: HCirV PCR positive in serum or plasma with cycle threshold (Ct) <36 and at least a partial HCirV genome fragment sequenced from serum or plasma. The stringent requirement for sequenced isolates eliminated spurious cases of nonspecific PCR positivity because we did not have positive sample controls for PCR reactions at the outset of this study. Clinical records of HCirV-infected persons were assessed for hepatitis at time of blood taking. If hepatitis was present, clinical, imaging, and diagnostic investigation data were independently assessed by 2 experts blinded to study goals to determine the cause of hepatitis.

Real-Time PCR, Sequencing, and Phylogenetic Analysis The HCirV real-time PCR targets the rep gene and was designed based on published genomes of HCirV strains from France (Paris strain) and China (YN09/ J030 and YN09/347 strains) (GenBank accession nos. ON677309, ON226770, and OP744467) (Appendix Table 2). We determined performance characteristics including limit-of-detection, linearity, and analytical specificity of the assay as previously described (10,11) and obtained partial HCirV genomes by using Sanger sequencing. If the viral load was sufficiently high by Sanger sequencing, we attempted complete genome sequencing (Appendix Table 3). For phylogenetic analysis, we obtained complete genomes of the 65 exemplar circovirus species as listed by the International Committee on Taxonomy of Viruses as of September 9, 2024, from the National Center for Biotechnology Information (NCBI) GenBank database. We also included an additional 3 complete HCirV genomes (GenBank accession nos. OP744467.1, ON226770.2, and OR905605.1) and those of 4 strains of Circovirus porcine 3 (PCV3; accession nos. MK095623, MK496297, MH277112, and MK496292). We downloaded 3 complete Cyclovirus genomes (accession nos. KT732787, KF031466, GQ404857) for use as an outgroup to root the phylogeny.

We performed multiple sequence alignment of the complete genomes using MAFFT version 7.526 software (-genfapair-maxiterate 1000-adjustdirectionaccurately) (12) and added partial genome sequences to the alignment with MAFFT (-localpair-addfragments-adjustdirectionaccurately) (13). We removed sites with >20% gaps with TrimAl version 1.4.22 (-gt 0.2) (14) and visualized the resulting alignment in JalView (15). We inferred a maximumlikelihood phylogenetic tree using IQ-TREE, using the best-fit substitution model automatically selected by ModelFinder and MixtureFinder (16,17; H. Ren et al., unpub. data, https://www.biorxiv.org/content /10.1101/2024.03.20.586035v2). We assessed branch support using the Shimodaira-Hasegawa-like approximate likelihood ratio test with 10,000 bootstrap replicates. We visualized and annotated the final phylogenetic tree using TreeViewer (18).

HCirV Peptide Expression, Characterization, and Immunoblots

The capsid (Cap) protein encoding the outer capsid of HCirV was expressed in *Escherichia coli*. Proteins were assessed using transmission electron microscopy and sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Cap protein was used to raise hyperimmune polyvalent serum samples in mice and IgM/IgG immunoblots of human serum samples as previously described (*19*) (Appendix).

Cell-Binding Assay

We seeded human hepatoma cells (PLC/PRF/5, ATCC CRL-8024; Hep-G2, ATCC CRL-10741) and A549 lung epithelial cells (CCL-185) on glass coverslips in a 24-well plate. When confluence reached 80%, we washed cells with prechilled 1× phosphate-buffered saline (PBS). We incubated Purified Cap protein (10 µg/well) VLPs and control proteins with PLC/PRF/5, Hep-G2, and A549 cells for 1 hour at 4°C. After discarding supernatant, we extensively washed cells with cold PBS 3-4 times to remove unbound VLPs and fixed with 4% paraformaldehyde, then incubated with mouse anti-Cap protein polyvalent immune serum (1:200) diluted in 1% BSA. We used Alexa Fluor 488-conjugated anti-mouse IgG (Thermo Fisher Scientific, https://www.thermofisher.com) as secondary antibody (1:2,000). We counterstained nuclei at AntiFade mounting medium with DAPI (VectorLabs, https://www.vectorlabs.com). We examined slides using a fluorescence microscope and used ImageJ software (https://imagej.net/ij) to measure positive cells.

Testing for Other Causes of Viral Hepatitis

We screened samples positive for HCirV DNA for other viral causes of hepatitis including hepatitis A virus, hepatitis B virus, HCV, hepatitis E virus (HEV), adenovirus, enterovirus, human herpesvirus (HHV) 6, HHV-7, CMV, HIV, and Epstein-Barr virus (EBV) using commercial or in-house-developed serologic and molecular assays (Appendix Table 4). Protocols for molecular assays have been published previously (*10,11,20-23*). We measured Torque teno virus (TTV) DNA using a published protocol (24).

Statistical Analysis

We compared proportions of HCirV-positive cases and controls using χ^2 or Fisher exact test, depending on the number of persons. To differentiate cholestatic from hepatocellular liver injury, we calculated the R factor as follows: (ALT value/ALT upper limit of normal) ÷ (ALP value/ALP upper limit of normal). R factor ≤2 corresponds to cholestatic injury, >2 to <5 represents a mixed pattern, and ≥5 corresponds to hepatocellular injury (25).

Results

Cases and Controls

We obtained serum or plasma samples from 278 hepatitis patients and 184 controls (Table 1). Immunosuppressed persons were well represented in both groups and accounted for more than half of all controls (Table 1). Degree of hepatitis was typically mild; most patients had anicteric hepatitis. A cause of hepatitis was identified by the clinical team in 123 (44.2%) cases; the remaining 155 (55.8%) were of unspecified etiology. For those with identified etiology, viral hepatitis (18.7%) and drug-induced liver injury (17.9%) were the most commonly diagnosed (Appendix Table 5).

Results of HCirV Screening in Human Samples

The limit-of-detection of the *Rep* gene real-time PCR was 600 copies/mL (Appendix Table 6) with good linearity (Appendix Figure 1). This result was

| Table 1. Clinical and demographic characteristics of he | epatitis cases and asymptomatic controls in study o | of human circovirus in |
|---|---|------------------------|
| patients with hepatitis, Hong Kong | | |
| Characteristic | Hepatitis cases, n = 278 | Controls, n = 184 |
| Median age, y (IQR) | 59 (46–69) | 53; 38.8 – 61 |
| Sex | | |
| Μ | 143 (51.4) | 96 (52.2) |
| F | 135 (48.6) | 88 (47.8) |
| Immunosuppression | 95 (34.2) | 117 (63.6) |
| Hemopoietic stem cell transplant | 24 | 32 |
| Solid organ transplant | 43 | 67 |
| HIV | 1 | 1 |
| Hematological malignancy | 14 | 14 |
| Cancer/chemotherapy | 8 | 0 |
| Other | 5 | 3 |
| Median ALT, U/L (IQR) | 126 (66.3–267.3) | NA |
| Median ALP, U/L (IQR) | 142 (97–240) | NA |
| Median total bilirubin, µmol/L (IQR) | 12 (8–30) | NA |

*Values are no. (%) except as indicated. ALP, alkaline phosphatase; ALT, alanine aminotransferase; IQR, interquartile range; NA, not applicable because all liver function parameters were below the upper limit of reference ranges (Appendix Table 2, https://wwwnc.cdc.gov/EID/article/30/12/24-1114-App1.pdf).



Figure 1. Results of screening in study of human circovirus in patients with hepatitis, Hong Kong. Ct, cycle threshold; HCirV, human circovirus.

comparable to the limit-of-detection in a recent study (26). We screened samples from hepatitis casepatients and from controls for HCirV infection using the *Rep* gene assay, followed by sequencing of positive samples. Of 278 hepatitis patients, 10 (3.6%) tested positive by HCirV PCR, but a sequence could not be obtained from 2 of those. Of the 184 controls, 1 (0.5%) tested positive for HCirV DNA, but a sequence could not be obtained (Figure 1). The 3 samples that tested positive by PCR without an identifiable sequence had high Ct values at >33. We did not regard those as HCirV infections for the purpose of this study.

HCirV Case Characteristics

The median age of 8 confirmed HCirV-infected persons (PCR-positive with identifiable sequences) was

| Table 2. Clinical and demographic characteristics of patients with human circovirus infection, Hong Kong* | | | | | | | | |
|---|---------------|----------|-----------|---------------|--------------|-----------|-------------|--------------|
| Patient no. | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| Age | 15 | 59 | 39 | 53 | 67 | 75 | 40 | 42 |
| Sex | М | М | F | F | Μ | М | М | F |
| Immunosuppressive | Neuroblastoma | None | None | Kidney graft† | Liver graft† | None | None | Liver graft† |
| condition | | | | | - | | | - |
| Organs / blood | Y | Ν | N | Y | Y | Ν | N | Y |
| products | | | | | | | | |
| Peak ALT, U/L | 672 | 413 | 109 | 96 | 532 | 469 | 401 | 983 |
| Peak ALP, U/L | 2288 | 139 | 174 | 928 | 601 | 274 | 484 | 168 |
| R factor | 0.6 | 4.7 | 1.6 | 0.3 | 1.4 | 3.2 | 1.6 | 15.2 |
| Peak bilirubin, µmol/L | 91 | 9 | 23 | 44 | 301 | 28 | 281 | 52 |
| Duration of hepatitis | Chronic | Acute | Acute | Acute | Acute, | Acute | Acute | Acute |
| | | | | | relapse | | | |
| Outcome | Death | Survived | Death | Survived | Death | Survived | Survived | Survived |
| Clinician diagnosis | NIC | NIC | NIC | NIC | Chronic | COVID-19 | Cholangitis | Anastomotic |
| | | | | | rejection | | | stricture |
| Expert 1 diagnosis | Drug-induced | NIC | Ischemic | Drug-induced | NIC | COVID-19 | Cholangitis | Rejection |
| | hepatitis | | hepatitis | cholestasis | | | | |
| Expert 2 diagnosis | NIC | NIC | NIC | NIC | NIC | Gallstone | Cholangitis | Anastomotic |
| | | | | | | | | stricture |

*ALP, alkaline phosphatase; ALT, alanine aminotransferase; NIC, no identifiable single cause for hepatitis. †Time from transplantation to hepatitis: patient 4, 1 month; patient 5, 15 years; patient 8, 22 months.



Figure 2. Liver function test kinetics in 8 patients with hepatitis and human circovirus infection, Hong Kong. A) Patient 1; B) patient 2; C) patient 3; D) patient 4; E) patient 5; F) patient 6; G) patient 7; H) patient 8. Black line indicates ALT, and green line indicates bilirubin. Plus signs indicate days when human circovirus DNA was detected in blood, whereas dashes indicate days when human circovirus DNA was not detected in blood. ALT, alanine aminotransferase.

47.5 years; 5 were male and 3 female (Table 2). A total of 4 patients had received an organ graft or blood transfusion within 3 months of hepatitis onset, and 4 persons were immunocompromised. None of the patients were known to be infected with HCV or HIV. R factor indicated cholestatic injury in 5 patients, mixed pattern in 2 persons, and hepatocellular injury in 1 person. Consensus on the cause of hepatitis was only available for 1 patient (patient 7); both experts (who were blinded to study objectives and HCirV screening results) agreed with the

clinical team on a diagnosis of cholangitis (Appendix Table 7). Investigations conducted for this study identified HEV viremia in 1 patient (patient 3) who had tested negative for HEV IgM (Appendix Table 7). Consensus on the cause of hepatitis in the other 6 patients was lacking. All but 1 patient had acute hepatitis that resolved within a month. HCirV DNA was detectable in plasma or serum of all patients on >1 day during episodes of hepatitis (except for patient 3, who had only 1 blood sample available for testing) (Figure 2). A total of 3 patients died; cause



Figure 3. Hematoxylin and eosin stained liver sections of patients in study of human circovirus in patients with hepatitis, Hong Kong. A, B) Cholestasis with bile pigment in zone 3 canaliculi (arrows) in patient 5 at original magnification $\times 10$ (A) and original magnification $\times 20$ (B). C) Acidophil body (blue arrow) with neutrophils around ducts (green arrow) in patient 8; original magnification $\times 10$.

of death was progression of underlying disease or unexplained cardiac arrest rather than hepatitis.

Of the 4 persons with immunosuppressive conditions, 3 were solid organ transplant recipients and1 was receiving chemotherapy for neuroblastoma (patient 1). Patient 1 had relapsing hepatitis episodes over 3 years before eventually dying of the underlying disease (Figure 2). HCirV was detected consistently in all plasma samples over a period of 18 months. Virus loads ranged from 5.65×10^3 copies/mL to 1.75×10^6 copies/mL. Patient 4 (kidney graft recipient) and patient 8 (liver graft recipient) also had persistent HCirV viremia over several months despite resolution of the initial hepatitis episode; viremia was highest during hepatitis (104-105 copies/mL) and declined as LFTs normalized in subsequent months. Archived plasma samples from patient 8 obtained at 1-month and 12-months after transplant tested negative for HCirV DNA, indicating an infection in the second year. Patient 5 (liver graft recipient) had acute hepatitis with transient HCirV DNA detection. Although the hepatitis relapsed around 3 months later, HCirV DNA was no longer detectable in the patient's plasma. The liver histology of patient 5 during the first hepatitis episode was consistent with cholestasis, whereas histology of patient 8 showed neutrophils around biliary ducts and acidophil bodies with no features of acute cellular rejection (Figure 3). Immunohistochemical staining for HCirV capsid protein on a small liver core biopsy from patients 5 and 8 did not show positive signals (Appendix Figure 2).

For some samples with sufficient volume, we also measured concomitant TTV viral load. HCirV was detected in 2 persons with undetectable TTV viremia. In patient 1, who had serial concomitant measures of HCirV and TTV viral loads, viral loads of HCirV tended to fluctuate much less than those of TTV, suggesting that HCirV is not merely an indirect measure of immunosuppression (Appendix Table 8).

The remaining 2 patients (patients 2 and 6) did not have immunosuppressive conditions. Patient 2, a 59-year-old man with good past health, was admitted with fever for 1 week and a maculopapular skin rash. In addition to hepatitis, blood tests revealed a lymphocytosis (3.8×10^9 cells/L) with occasional atypical lymphocytes. Serologic workup for known causes of infectious mononucleosis including EBV, CMV, and HIV yielded negative results (Appendix Table 7). The peripheral blood EBV viral load was detected at <100 IU/mL. Patient 6 was a 75-year-old man admitted for fever. Blood tests showed parenchymal liver dysfunction (Figure 2). Nasopharyngeal swab samples tested positive for SARS-CoV-2 by reverse transcription PCR with a Ct value of 30.4. Chest radiograph did not show lower respiratory tract involvement, and he did not require supplemental oxygen. Ultrasound showed a gallstone but no cholecystitis or cholangitis.

HCirV Genome and Phylogenetic Analysis

Complete HCirV genome was obtained for patient 1 (GenBank accession no. PP968832). Predicted genomic organization of this strain was like other circovirus strains: 2 major open reading frames (ORFs) encoding the Rep gene at nucleotide positions (nt) 247-1134 and capsid protein at nt 1368-2012. The Rep gene is encoded on the sense strand and the *Cap* gene on the antisense strand. The genome size is 2021 bp, and it is most closely related to the HCirV1 Paris strain (Gen-Bank accession no. ON677309.1), sharing a nucleotide identity of 98.7%. Partial gene sequences were obtained from all the other patients (Appendix Table 9). A phylogenetic tree of complete HCirV genome of patient 1 (HK P1) and partial gene sequences of other isolates showed that strains related to both Paris and Yunnan strains circulate in Hong Kong (Figure 4).

HCirV Immunoassays

HCirV Cap protein was expressed in *E. coli*. This peptide showed a band at 25 kDa on SDS-PAGE (Appendix Figure 3, panel A). The peptides spontaneously assembled into VLPs on transmission electron microscopy (Appendix Figure 3, panel B). Serum samples from 7 HCirV-infected persons were available for antibody immunoassays using HCirV VLP-based immunoblots (Figure 5). All patients were negative on IgM immunoblots. Four patients had discernible bands on IgG immunoblots (patients 1, 4, 7, and 8); of those, 3 patients were immunocompromised. As negative controls, we used 9 HCirV PCR-negative donor samples, as well as a serum pool of 900 healthy donors. None of those samples showed bands in the immunoblot, suggesting reasonable specificity (Appendix Figure 3, panel C).

HCirV Cell-Binding Assay

To further investigate hepatic tropism of HCirV, we tested whether HCirV VLPs could bind to hepatoma cells (PLC/PRF/5). HEV VLPs that are known to bind strongly to PLC/PRF/5 cells served as positive controls. SARS-CoV-2 nucleoprotein served as negative controls. HCirV VLPs were capable of binding to PLC/PRF/5 cells (Figure 6). We found that 27/90 (30%) of cells bound to HCirV VLPs, compared with 30/468 (6.4%) cells that bound to HEV VLPs. We confirmed that HCirV VLPs could bind with Hep-G2, another hepatoma cell line (Appendix Figure 4). Of note, no binding was observed with A549, a lung epithelial cell line (Appendix Figure 4).

Discussion

The association between HCirV and hepatitis requires careful evaluation. Many human DNA viruses have been classified as orphan viruses despite initial discovery in diseased patient cohorts (27–29). Prominent examples in-

clude anelloviruses and pegiviruses, which were initially believed to be associated with hepatitis but are now generally considered to be nonpathogenic (*30–33*).

In this study, we identified HCirV infections in 1.7% of all screened persons using our stringent case



Figure 4. Phylogenetic tree of representative circoviruses and human circoviruses from study of human circovirus in patients with hepatitis, Hong Kong. Maximum-likelihood phylogenetic tree was inferred from a multiple sequence alignment of complete representative *Circovirus* genomes and a mixture of full-length and partial genome sequences from this study (red text) using IQ-TREE (*16*). Three representative species of *Cyclovirus* were used as an outgroup for rooting the tree. Branch supports were assessed using the Shimodaira-Hasegawa–like approximate likelihood ratio test with 10,000 bootstrap replicates. Branches with <80% support were collapsed. Scale bar indicates nucleotide substitutions per site.

definition of PCR positivity with sequenced partial genome. Some persons with high Ct value without identifiable sequences could feasibly have had genuine resolving HCirV infection, in which case the prevalence of HCirV infection in our cohort would be even higher.

Confirming the association between HCirV infection and hepatitis was not straightforward. Alternative explanations for deranged liver function were present in some HCirV patients. However, we could not rule out that HCirV contributed to hepatitis in other cases because of lack of alternate diagnoses, suggestive liver histology, and negative workup for other causes of hepatitis. The case of patient 2, who had an infectious mononucleosis-like syndrome, was particularly striking because of the presence of clinical manifestations that were compatible with acute viral illness. Most infectious mononucleosislike syndromes are caused by primary/acute EBV, CMV, HIV, and human herpesvirus 6 infections. However, case reports of infectious mononucleosislike symptoms during noncanonical viral infections such as mpox, parvovirus B19, and human metapneumovirus are also described (34-36). Therefore, we believe that the infectious mononucleosis-like



Figure 5. IgM and IgG immunoblots of 7 patients for whom sufficient serum was available from study of HCirV in patients with hepatitis, Hong Kong. P indicates positive control, mouse polyclonal serum raised against HCirV cap protein. N indicates HCirV PCR-negative human donor sample. HCirV, human circovirus.

syndrome in patient 2 was attributable to HCirV. Such clinical manifestations might represent distinctive host responses in a minority of infected patients. We described cholestasis and neutrophil infiltrates in liver tissue of our HCirV-infected patients, which was distinct from the hepatitis with mixed inflammatory infiltrates described by Pérot et al. (7) and Hamelin et al. (37) in HCirV-infected patients. Those results might represent distinct histopathological findings caused by this virus.



Figure 6. Cell-binding assay showing binding of HCirV VLPs to PLC/PRF/5 cells in study of HCirV in patients with hepatitis. HEV VLPs (*b*HEV p239) is included as a positive control; SARS-CoV-2 NP protein is included as a negative control. Nuclei are counterstained with DAPI. Cap, capsid; HCirV, human circovirus; HEV, hepatitis E virus; NP, nucleoprotein; VLP, virus-like particle.

On the basis of the pathobiology of other circoviruses, HCirV human infections could run the gamut from silent infection to well-defined clinical syndromes with complex virus-host interactions determining clinical phenotype (*38*). Detailed surveillance and case descriptions will be required to elucidate the clinical spectrum of this virus. We demonstrate here that HCirV VLPs can bind to liver cells. Tropism for immune cells (like PCV3) could lead to complex virus-host interplay and cytokine dysregulation leading to liver dysfunction (*39*). The role of co-infections and other inflammatory stimuli in HCirV reactivation cannot be excluded. Of the patients reported in this study, 2 had HEV and COVID-19 concomitantly.

In this study, we confirm that HCirV can cause persistent infection. Of note, LFTs can normalize despite ongoing viremia. Because half the HCirV patients identified in this study were immunocompromised, we speculate that HCirV might establish latency and reactivate during immunosuppression. Another possibility is that those patients acquired HCirV through contaminated blood or organ grafts. We were unable to access blood and organ donor data to evaluate this possibility. Furthermore, a large international study involving >200,000 plasma donations did not find evidence of HCirV contamination (26). However, on the basis of the relatively higher HCirV detection rate in our study, we cannot rule out that prevalence might be higher in our locality. We speculate whether HCirV might be a previously unidentified porcine circovirus capable of zoonotic transmission. PCV3 has been shown to be transmissible to nonhuman primates through xenotransplantation (40).

The first limitation of our study was that we were not able to identify sequences in 3 HCirV PCR-positive samples. Those cases might have been genuine infection cases at early convalescence. The use of rolling circle amplification using a phi29 DNA polymerase would have helped us resolve some of these cases. Other limitations of our study include its retrospective nature; we could not track kinetics of infection in most cases because samples were not available. Liver biopsy was also not available for most cases because of the mild nature of hepatitis. Only small core biopsies of tissue were available from patients 5 and 8, which could explain negative immunohistochemical staining. In situ hybridization would have been a more sensitive approach.

Although not definitive, we believe our findings support further investigation of HCirV as a cause of hepatitis in a proportion of infected human hosts. Larger case-control studies, liver tissue analysis, and infectious disease models are required to investigate this association further. Clinicians should be aware of this new evidence that HCirV could be a cause of hepatitis in some infected individuals.

This research was supported by the Partnership Programme on Enhancing Laboratory Surveillance and Investigation of Emerging Infectious Diseases and Antimicrobial Resistance for Department of Health, the HKUMed Research Fellowship Scheme for Clinical Academics, Lo Ying Shek Chi Wai Foundation Award for Young Investigator 2022-23, and the UGC Seed Fund for PI Research-Basic Research 2023/24.

About the Author

Mr. Wu is a master of philosophy student at the University of Hong Kong, China. His primary research interest is investigating emerging agents of viral hepatitis from a clinical-translational perspective.

References

- Bernal W, Auzinger G, Dhawan A, Wendon J. Acute liver failure. Lancet. 2010;376:190–201. https://doi.org/10.1016/ S0140-6736(10)60274-7
- Ho A, Orton R, Tayler R, Asamaphan P, Herder V, Davis C, et al.; DIAMONDS Consortium; ISARIC4C Investigators. Adeno-associated virus 2 infection in children with non-A-E hepatitis. Nature. 2023;617:555–63. https://doi.org/10.1038/ s41586-023-05948-2
- Sridhar S, Yip CCY, Wu S, Cai J, Zhang AJ, Leung KH, et al. Rat hepatitis E virus as cause of persistent hepatitis after liver transplant. Emerg Infect Dis. 2018;24:2241–50. https://doi.org/10.3201/eid2412.180937
- Rivero-Juarez A, Frias M, Perez AB, Pineda JA, Reina G, Fuentes-Lopez A, et al.; HEPAVIR and GEHEP-014 Study Groups. Orthohepevirus C infection as an emerging cause of acute hepatitis in Spain: first report in Europe. J Hepatol. 2022;77:326–31. https://doi.org/10.1016/j.jhep.2022.01.028
- Sridhar S, Yip CCY, Lo KHY, Wu S, Situ J, Chew NFS, et al. Hepatitis E virus species C infection in humans, Hong Kong. Clin Infect Dis. 2022;75:288–96. https://doi.org/10.1093/ cid/ciab919
- Li Y, Cao L, Ye M, Xu R, Chen X, Ma Y, et al. Plasma virome reveals blooms and transmission of anellovirus in intravenous drug users with HIV-1, HCV, and/or HBV infections. Microbiol Spectr. 2022;10:e0144722. https://doi.org/10.1128/spectrum.01447-22
- Pérot P, Fourgeaud J, Rouzaud C, Regnault B, Da Rocha N, Fontaine H, et al. Circovirus hepatitis infection in heart-lung transplant patient, France. Emerg Infect Dis. 2023;29:286–93. https://doi.org/10.3201/eid2902.221468
- Varsani A, Harrach B, Roumagnac P, Benkő M, Breitbart M, Delwart E, et al. 2024 taxonomy update for the family Circoviridae. Arch Virol. 2024;169:176. https://doi.org/ 10.1007/s00705-024-06107-2
- 9. Li Y, Zhang P, Ye M, Tian RR, Li N, Cao L, et al. Novel circovirus in blood from intravenous drug users, Yunnan, China. Emerg Infect Dis. 2023;29:1015–9. https://doi.org/10.3201/eid2905.221617

- Wong SSY, Yip CCY, Sridhar S, Leung KH, Cheng AKW, Fung AMY, et al. Comparative evaluation of a laboratorydeveloped real-time PCR assay and RealStar Adenovirus PCR Kit for quantitative detection of human adenovirus. Virol J. 2018;15:149. https://doi.org/10.1186/ s12985-018-1059-7
- Yip CCY, Sridhar S, Cheng AKW, Fung AMY, Cheng VCC, Chan KH, et al. Comparative evaluation of a laboratory developed real-time PCR assay and the RealStar HHV-6 PCR Kit for quantitative detection of human herpesvirus 6. J Virol Methods. 2017;246:112–6. https://doi.org/10.1016/ j.jviromet.2017.05.001
- Katoh K, Standley DM. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol Biol Evol. 2013;30:772–80. https://doi.org/ 10.1093/molbev/mst010
- Katoh K, Frith MC. Adding unaligned sequences into an existing alignment using MAFFT and LAST. Bioinformatics. 2012;28:3144–6. https://doi.org/10.1093/bioinformatics/ bts578
- Capella-Gutiérrez S, Silla-Martínez JM, Gabaldón T. trimAl: a tool for automated alignment trimming in large-scale phylogenetic analyses. Bioinformatics. 2009;25:1972–3. https://doi.org/10.1093/bioinformatics/btp348
- Waterhouse AM, Procter JB, Martin DMA, Clamp M, Barton GJ. Jalview Version 2 – a multiple sequence alignment editor and analysis workbench. Bioinformatics. 2009;25:1189–91. https://doi.org/10.1093/bioinformatics/ btp033
- Minh BQ, Schmidt HA, Chernomor O, Schrempf D, Woodhams MD, von Haeseler A, et al. IQ-TREE 2: new models and efficient methods for phylogenetic inference in the genomic era. Mol Biol Evol. 2020;37:1530–4. https://doi.org/ 10.1093/molbev/msaa015
- Kalyaanamoorthy S, Minh BQ, Wong TKF, von Haeseler A, Jermiin LS. ModelFinder: fast model selection for accurate phylogenetic estimates. Nat Methods. 2017;14:587–9.
- Bianchini G, Sánchez-Baracaldo P. TreeViewer: flexible, modular software to visualise and manipulate phylogenetic trees. Ecol Evol. 2024;14:e10873. https://doi.org/10.1002/ ece3.10873
- Sridhar S, Situ J, Cai JP, Yip CC, Wu S, Zhang AJ, et al. Multimodal investigation of rat hepatitis E virus antigenicity: implications for infection, diagnostics, and vaccine efficacy. J Hepatol. 2021;74:1315–24. https://doi.org/10.1016/ j.jhep.2020.12.028
- Sridhar S, Yip CC, Wu S, Chew NF, Leung KH, Chan JF, et al. Transmission of rat hepatitis E virus infection to humans in Hong Kong: a clinical and epidemiological analysis. Hepatology. 2021;73:10–22. https://doi.org/ 10.1002/hep.31138
- Yip CCY, Sridhar S, Leung KH, Cheng AKW, Chan KH, Chan JFW, et al. Evaluation of RealStar *Alpha* Herpesvirus PCR Kit for detection of HSV-1, HSV-2, and VZV in clinical specimens. BioMed Res Int. 2019;2019:5715180. https://doi.org/10.1155/2019/5715180
- Sridhar S, Chung TWH, Chan JFW, Cheng VCC, Lau SKP, Yuen KY, et al. Emergence of cytomegalovirus mononuc leosis syndrome among young adults in Hong Kong linked to falling seroprevalence: results of a 14-year seroepidemiological study. Open Forum Infect Dis. 2018;5:ofy262. https://doi.org/10.1093/ofid/ofy262
- 23. Smith C, Tsang J, Beagley L, Chua D, Lee V, Li V, et al. Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. Cancer

Res. 2012;72:1116–25. https://doi.org/10.1158/ 0008-5472.CAN-11-3399

- 24. Maggi F, Pifferi M, Fornai C, Andreoli E, Tempestini E, Vatteroni M, et al. TT virus in the nasal secretions of children with acute respiratory diseases: relations to viremia and disease severity. J Virol. 2003;77:2418–25. https://doi.org/10.1128/JVI.77.4.2418-2425.2003
- Kwo PY, Cohen SM, Lim JK. ACG clinical guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol. 2017;112:18–35. https://doi.org/10.1038/ajg.2016.517
- Pérot P, Da Rocha N, Farcet MR, Kreil TR, Éloit M. Human circovirus is not detected in plasma pools for fractionation. Transfusion. 2024;64:16–8. https://doi.org/ 10.1111/trf.17604
- Sridhar S, To KK, Chan JF, Lau SK, Woo PC, Yuen KY. A systematic approach to novel virus discovery in emerging infectious disease outbreaks. J Mol Diagn. 2015;17:230–41. https://doi.org/10.1016/j.jmoldx.2014.12.002
- Smits SL, Zijlstra EE, van Hellemond JJ, Schapendonk CM, Bodewes R, Schürch AC, et al. Novel cyclovirus in human cerebrospinal fluid, Malawi, 2010-2011. Emerg Infect Dis. 2013;19:1511-3. https://doi.org/10.3201/ eid1909.130404
- Lim ES, Reyes A, Antonio M, Saha D, Ikumapayi UN, Adeyemi M, et al. Discovery of STL polyomavirus, a polyomavirus of ancestral recombinant origin that encodes a unique T antigen by alternative splicing. Virology. 2013;436:295–303. https://doi.org/10.1016/j.virol.2012.12.005
- Deinhardt F, Holmes AW, Capps RB, Popper H. Studies on the transmission of human viral hepatitis to marmoset monkeys. I. Transmission of disease, serial passages, and description of liver lesions. J Exp Med. 1967;125:673–88. https://doi.org/10.1084/jem.125.4.673
- Nishizawa T, Okamoto H, Konishi K, Yoshizawa H, Miyakawa Y, Mayumi M. A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology. Biochem Biophys Res Commun. 1997;241:92–7. https://doi.org/ 10.1006/bbrc.1997.7765
- Sridhar S, Yip CCY, Chew NFS, Wu S, Leung KH, Chan JFW, et al. Epidemiological and clinical characteristics of human hepegivirus 1 infection in patients with hepatitis C. Open Forum Infect Dis. 2019;6:ofz329. https://doi.org/10.1093/ ofid/ofz329
- Berg MG, Lee D, Coller K, Frankel M, Aronsohn A, Cheng K, et al. Discovery of a novel human pegivirus in blood associated with hepatitis C virus co-infection. PLoS Pathog. 2015;11:e1005325. https://doi.org/10.1371/ journal.ppat.1005325
- Li IW, To KK, Tang BS, Chan KH, Hui CK, Cheng VC, et al. Human metapneumovirus infection in an immunocompetent adult presenting as mononucleosis-like illness. J Infect. 2008;56:389–92. https://doi.org/10.1016/ j.jinf.2008.03.005
- Chiu KH, Wong SC, Tam AR, Sridhar S, Yip CC, Chan KH, et al. The first case of monkeypox in Hong Kong presenting as infectious mononucleosis-like syndrome. Emerg Microbes Infect. 2023;12:2146910. https://doi.org/10.1080/ 22221751.2022.2146910
- Muñoz-Gómez S, Cunha BA. Parvovirus B19 mimicking Epstein-Barr virus infectious mononucleosis in an adult. Am J Med. 2013;126:e7–8. https://doi.org/10.1016/ j.amjmed.2012.12.010
- Hamelin B, Pérot P, Pichler I, Haslbauer J, Hardy D, Hing D, et al. Circovirus hepatitis in immunocompromised patient, Switzerland. Emer Infect Dis. 2024;30:2140–4.

- da Silva RR, da Silva DF, da Silva VH, de Castro AMMG. Porcine circovirus 3: a new challenge to explore. Front Vet Sci. 2024;10:1266499. https://doi.org/10.3389/ fvets.2023.1266499
- Chen D, Zhang L, Xu S. Pathogenicity and immune modulation of porcine circovirus 3. Front Vet Sci. 2023; 10:1280177. https://doi.org/10.3389/fvets.2023.1280177
- 40. Krüger L, Längin M, Reichart B, Fiebig U, Kristiansen Y, Prinz C, et al. Transmission of porcine circovirus 3 (PCV3)

by xenotransplantation of pig hearts into baboons. Viruses. 2019;11:650. https://doi.org/10.3390/v11070650

Address for correspondence: Siddharth Sridhar, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong 19-026, Block T, 102 Pokfulam Rd, Hong Kong, China; email: sid8998@hku.hk

- Flexible Development Programs for Antibacterial Drugs to Address Unmet Medical Needs
- Conceptual Framework for Community-Based Prevention of Brown Dog Tick–Associated Rocky Mountain Spotted Fever
- Reemergence of Oropouche Virus in the Americas and Risk for Spread in the United States and Its Territories, 2024
- Clinical and Genomic Epidemiology of Coxsackievirus A21 and Enterovirus D68 in Homeless Shelters, King County, Washington, USA, 2019–2021
- Mortality Rates after Tuberculosis Treatment, Georgia, USA, 2008–2019
- *Vibrio parahaemolyticus* Foodborne Illness Associated with Oysters, Australia, 2021–2022
- Wastewater Surveillance for Poliovirus in Selected Jurisdictions, United States, 2022–2023
- Rocky Mountain Spotted Fever in Children along the US–Mexico Border, 2017–2023
- Extrapulmonary *Mycobacterium abscessus* Infections, France, 2012–2020
- Antiviral Susceptibility of Swine-Origin Influenza A Viruses Isolated from Humans, United States



EMERGING INFECTIOUS DISEASES



- Risk for Facial Palsy after COVID-19 Vaccination, South Korea, 2021–2022
- Detection in Orchards of Predominant Azole-Resistant Candida tropicalis Genotype Causing Human Candidemia, Taiwan
- Spatiotemporal Ecologic Analysis of COVID-19 Vaccination Coverage and Outcomes, Oklahoma, USA, February 2020–December 2021
- SARS-CoV-2 Infection in School Settings, Okinawa Prefecture, Japan, 2021–2022
- Quantitative SARS-CoV-2 Spike Receptor-Binding Domain and Neutralizing Antibody Titers in Previously Infected Persons, United States, January 2021–February 2022

- Estimating Influenza Illnesses Averted by Year-Round and Seasonal Campaign Vaccination for Young Children, Kenya
- Fatal Oropouche Virus Infections in Nonendemic Region, Brazil, 2024
- Co-Circulation of 2 Oropouche Virus Lineages, Amazon Basin, Colombia, 2024
- Analysis of Monkeypox Virus Exposures and Lesions by Anatomic Site
- Emerging Monkeypox Virus Sublineage C.1 Causing Community Transmission, Vietnam, 2023
- Dengue Outbreak Caused by Multiple Virus Serotypes and Lineages, Colombia, 2023–2024
- Evidence of Human Bourbon Virus Infections, North Carolina, USA
- Clinical and Molecular Characterization of *Human Burkholderia* mallei Infection, Brazil
- Computerized Decision Support Systems Informing Community-Acquired Pneumonia Surveillance, France, 2017–2023
- Invasive Group A *Streptococcus* Hypervirulent M1UK Clone, Canada, 2018–2023
- Suspected Acute Pulmonary Coccidioidomycosis in Traveler

To revisit the November 2024 issue, go to: https://wwwnc.cdc.gov/eid/articles/issue/30/11/table-of-contents

Article DOI: https://doi.org/10.3201/eid3012.241114

EID cannot ensure accessibility for supplementary materials supplied by authors. Readers who have difficulty accessing supplementary content should contact the authors for assistance.

Human Circovirus in Patients with Hepatitis, Hong Kong

Appendix

Supplemental Material

Human circovirus (HCirV) real time PCR

Total nucleic acid was extracted from samples using the EZ1 Virus Mini Kit v2.0 (Qiagen, Hilden, Germany). Real-time PCR assays were performed using QuantiNova Probe PCR Kit (Qiagen) in a LightCycler 480 II Real-Time PCR System (Roche, Basel, Switzerland). Each 20 μ l-reaction mix contained 1x QuantiNova Probe PCR Master Mix, 0.4 μ M of forward and reverse primers, 0.2 μ M probe and 5 μ L template DNA. Reactions were incubated at 95°C for 2 min, followed by 45 cycles at 95°C for 5 s and 60°C for 30 s. Quantitation was achieved using plasmid standards prepared using the pCR2.1-TOPO vector (Invitrogen, Carlsbad, USA) cloned with a circovirus replication-associated protein (*Rep*) gene fragment. Plasmid concentrations ranging from $10^2 - 10^6$ copies/reaction were used to generate a standard curve for each qPCR run.

Sequencing of human circovirus (HCirV)

HCirV strains were sequenced using Sanger sequencing. Complete genome amplification of human circovirus was performed using primers listed in Appendix Table 2. The PCR mixture (25 μ L) contained sample DNA extract, 1X PCR buffer II, 2 mM MgCl₂, 200 μ M of each dNTP, 1 μ M of each forward and reverse primer and 0.625 U of AmpliTaq Gold DNA polymerase (Applied Biosystems, MA, USA). PCR was performed using a thermocycler (Applied Biosystems) with a hot start at 95°C for 10 min, followed by 45 cycles of 94°C for 1 min, 55°C for 1 min, and 72°C for 1 min and a final extension at 72°C for 10 min. The PCR products were detected by agarose gel electrophoresis and those of correct size were subjected to DNA purification using QIAquick gel extraction kit (QIAGEN). Both strands of the PCR products were sequenced twice with an ABI Prism 3500 Genetic Analyzer (Applied Biosystems) using primers listed in Appendix Table 2. Sequences were assembled and manually edited to produce final sequences of the viral genomes by BioEdit version 7.2.5 (NC State University, Raleigh).

Expression of HCirV cap peptide

The *Cap* gene sequence derived from the YN09/J030 HCirV strain (GenBank accession no.: ON226770) was optimized and cloned into a pET-28a(+) vector (Sangon Biotech, Shanghai, People's Republic of China). Recombinant pET28+-Cap plasmid was transformed into *E. coli* BL21 (DE3) and single colonies were grown in LB medium with 50 g/ml kanamycin at 37°C overnight with shaking at 250 rpm. The culture was diluted 1:20 in 500 ml fresh LB medium and incubated at 37 °C at 250 rpm until optical density at 600 nm (OD600) was 0.6–0.8. Isopropyl - d-thiogalactopyranoside (IPTG) was added to a final concentration of 0.5 mM with incubation overnight at 16°C. Cells were harvested by centrifugation at 8000 × g for 10 min at 4 °C. The cell pellet was washed in 100 ml of 0.1% Triton in phosphate buffered saline (PBS). After centrifugation, cell pellets were resuspended in 100 mL lysis buffer and sonicated on ice using Soniprep 150. Lysates were divided into supernatant and pellet by centrifugation at 10,000 × g for 20 min at 4°C. Supernatant was collected and purified by His PurNI-NTA Resin (Thermo Fisher Scientific, Waltham, USA). Expression and solubility of Cap protein was analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and Coomassie blue staining on a 15% polyacrylamide gel.

Soluble Cap protein was purified by ENrich SEC 650 10x300 column (Bio Red NGC chromatography system). Protein samples were separated at a flow rate of 0.5 ml/min. Fraction aliquots were analyzed by 12% SDS-PAGE and Western blotting. Protein concentrations were determined by Bradford assay (Bio-Rad, Hercules, USA) using bovine serum albumin (BSA) as a standard. Fractions containing purified protein were pooled and stored at 4°C.

Transmission electron microscopy

Cap protein was ultracentrifuged using Amicon Ultra-0.5 tubes (Merck, New Jersey, USA) according to manufacturer instructions. The filtrate was adsorbed onto a glow-discharged

formvar/carbon support grids for 5 minutes, then stained with 3% phosphotungstic acid for 30 seconds. Grids were examined using a transmission electron microscope (Philips CM100).

Polyvalent murine anti-cap antisera

Cap protein (10 ug) was mixed with an equal volume of QuickAntibody adjuvant (Biodragon Immunotechnologies, Beijing, People's Republic of China; Cat# KX0210042) in advance. Six-week-old female BALB/c mice (n = 2) were immunized intramuscularly with the protein, and then boosted intramuscularly at day 14. On day 38, blood was harvested and spun down to separate serum, which served as controls for the immunoblot experiments.

HCirV IgM and IgG immunoblots

HCirV cap proteins separated by SDS-PAGE were transferred onto a nitrocellulose membrane (Immobilon 0.45 µm; Merck Millipore, Burlington, USA). After blocking 10% skim milk in 0.3% TPBS, the membrane was incubated with different antibodies/ sera lane-by-lane using the Mini-PROTEAN II Multiscreen Apparatus (BIO-RAD) at room temperature for 1 h (human sera (1:100) or mouse sera (1:2000)). The blots were then washed in 0.3% TPBS and exposed to horseradish peroxidase (HRP)-conjugated secondary antibodies. After washing, membranes were visualized using the Luminescent image analyzer (GE Healthcare, Chicago, USA).

Analytical characteristics of the HCirV PCR assay

The limit of detection (LOD) of the HCirV real-time PCR assay was evaluated using 2fold serial dilutions of a sample extract or a plasmid containing the target insert ranging from 1.25 copies/reaction to 40 copies/reaction. Each concentration was tested in 8 replicates (Appendix Table 5). The LOD of the circovirus real-time PCR assays targeting *Cap* and *Rep* gene regions were 5 copies/reaction and 10 copies/reaction, respectively. Both assays did not cross-react with samples containing HAV, HBV, HCV, HEV, herpes simplex virus (HSV-1), HSV-2, varicella zoster virus (VZV), CMV, EBV, HHV-6, and enterovirus. Linearity of the *Rep* gene assay used for screening human samples was evaluated by analyzing a dilution series of the plasmid with various concentrations (Appendix Figure 1). Circovirus DNA quantitation by the in-house circovirus qPCR assay was linear ($R^2 = 0.9989$) across approximately eight orders of magnitude, ranging from 10 to 10^8 copies/reaction. Therefore, the analytical characteristics of HCirV real-time PCR assays was considered sufficient to screen samples.

References

1. Pérot P, Fourgeaud J, Rouzaud C, Regnault B, Da Rocha N, Fontaine H, et al. Circovirus hepatitis infection in heart-lung transplant patient, France. Emerg Infect Dis. 2023;29:286-93. PubMed https://doi.org/10.3201/eid2902.221468

Appendix Table 1. Upper limits of reference ranges for liver function tests used in this study

| Liver function test | Male | Female |
|-------------------------------------|------|--------|
| Alkaline phosphatase (U/L) | 110 | 93 |
| Alanine aminotransferase (U/L) | 58 | 36 |
| Aspartate aminotransferase (U/L) | 38 | 30 |
| Total bilirubin (µmol/L) | 23 | 23 |
| Gamma-glutamyl transpeptidase (U/L) | 62 | 35 |

Appendix Table 2. Primers and probes for human circovirus detection used in this study*

| | | | j | |
|------------------------|-------------|---------|----------------------------------|-------------------|
| Assay | Gene target | | Primer / probe sequence (5'- 3') | Product size (bp) |
| Human sample screening | Rep | Forward | GTGTTTTACGATMAACAACTGGAC | 145 bp |
| | | Reverse | GTTCTTGAAATTCACGTAYCCTTG | |
| | | Probe | HEX- TATCGGCARAGAGGTTGGAA-IABkFQ | |
| *bp, base pairs. | | | | |

*bp, base pairs.

Appendix Table 3. Primers used for Sanger sequencing of human circovirus*

| Primer name | Sequence (5' - 3') | Position |
|---|--|---------------------------|
| HcirV-YN-F1 | CTGGAACCAGGAGGAAGATTGAG | 25–47 |
| HCirV1_101F | GAGCAAGGTGCTGTATGGTG | 101–120 |
| HCirV1-F3 | GTGTTTTACGATMAACAACTGGAC | 276–299 |
| HCirV1-R3 | GTTCTTGAAATTCACGTAYCCTTG | 397–420 |
| HCirV1_rep-330F | TGGCAAAGAGAAAGCGAAGTA | 330–350 |
| HcirV-YN-R1 | TGTTCTTGAAATTCACGTATCCTTGC | 396–421 |
| HCirV1_rep-555R | GCCACTCTCTCCAATCTCCA | 536–555 |
| HCirV1_rep-902R | TCATCATAAGGAACCCACCCA | 882–902 |
| HCirV1-F2 | GATGGCTATGATGGGGAGG | 838–856 |
| HCirV1-R2 | CCCCTTAACAGGAACCTTCA | 932–951 |
| HCirV1_rep-882F | TGGGTGGGTTCCTTATGATGA | 882–902 |
| HCirV1_capsid-1562R | CCTCTCATCCATCTTACTGGCA | 1541–1562 |
| HCirV1-Rv1† | AGAGTTCCACCAGGTTCTGC | 1484–1504 |
| HCirV1-Fw1† | ACCTGGATGGACCCTGGAAT | 1659–1678 |
| HCirV1_capsid-1590F | TCTGTTAGCCTTCCAAAGTCTG | 1590–1611 |
| HCirV1_rep-350R | TACTTCGCTTTCTCTTTGCCA | 330–350 |
| *Primer position corresponding to the genor | ne sequence of Human circovirus 1 strain Paris (GenBank: ON677309.1). F in | dicates forward primer; R |
| indicates reverse primer. | | |
| +Primers designed by Pérot et al. (1). | | |

Appendix Table 4. Methodology of testing of agents of viral hepatitis

| Pathogen | Assay (manufacturer) |
|-----------------------------|--|
| Hepatitis A virus | Vidas anti-HAV IgM (bioMérieux, Marcy-l'Étoile, France) |
| Hepatitis B virus | Alinity HBsAg (Abbott, Chicago, USA) |
| | Alinity Anti-HBc (Abbott) |
| | Cobas 4800 System HBV DNA (Roche, Basel, Switzerland) |
| Hepatitis C virus | Anti-HCV (Abbott) |
| Hepatitis E virus | HEV IgM (Wantai, Beijing, People's Republic of China) |
| | In-house developed real-time RT-PCRs targeting Paslahepevirus balayani and Rocahepevirus |
| | ratti |
| Epstein-Barr virus | In-house developed real-time PCR assay |
| Human cytomegalovirus (CMV) | Vidas anti-CMV IgM (bioMérieux) |
| | In-house developed pp65 antigen or real-time PCR assay |
| Human herpesvirus 6 | In-house developed real-time PCR assay |
| Human herpesvirus 7 | In-house developed real-time PCR assay |
| Adenovirus | In-house developed real-time PCR assay |
| Enterovirus | In-house developed real-time RT-PCR assay |

Appendix Table 5. Causes of hepatitis in patients with hepatitis of known etiology (n = 123), Hong Kong Special Administrative Region, People's Republic of China

| Cause of hepatitis | Number (%) |
|--|------------|
| Metabolic dysfunction-associated steatotic liver disease | 11 (8.9) |
| Gallstone disease / acute cholangitis / liver abscess | 17 (13.8) |
| Alcohol-related liver disease | 3 (2.4) |
| Drug-induced liver injury | 22 (17.9) |
| Acute cellular rejection of graft liver | 7 (5.7) |
| Autoimmune hepatitis | 2 (1.6) |
| Graft versus host disease | 11 (8.9) |
| Malignancy | 7 (5.7) |
| Viral hepatitis | 23 (18.7) |
| HAV | 1 |
| HBV | 13 |
| HCV | 4 |
| HEV | 5 |
| Systemic causes (including shock, post-cardiac arrest, right-sided heart failure, thyrotoxic hepatitis, systemic | 17 (13.8) |
| infections) | |
| Acute pancreatitis | 2 (1.6) |
| Polycystic liver disease | 1 (0.8) |

Appendix Table 6. Determining limits of detection (LOD) of the human circovirus PCR assay used in this study*

| | Result | | | | | | | |
|--|--------|--------|--------|--------|--------|--------|--------|--------|
| Concentration (copies/reaction) | Test 1 | Test 2 | Test 3 | Test 4 | Test 5 | Test 6 | Test 7 | Test 8 |
| Rep gene assay | | | | | | | | |
| 40 | + | + | + | + | + | + | + | + |
| 20 | + | + | + | + | + | + | + | + |
| 10 | + | + | + | + | + | + | + | + |
| 5 | - | + | + | + | + | _ | _ | - |
| 2.5 | _ | + | — | + | + | + | — | + |
| 1.25 | - | + | — | — | — | + | + | — |
| NTC | - | - | _ | _ | _ | _ | _ | _ |
| *NTC, no template control; +, detected; -, not detected. | | | | | | | | |

| Patient | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
|--------------------|-----------------------|----------------|----------|-------------------|-------------------|------------------|--------------------|--------------------|
| HAV IgM | N | N | Ν | N | N | N | N | N |
| HBsAg | N | N | Ν | N | N | N | N | N |
| Anti-HBc | N | N | Ν | Р | N | Р | N | N |
| HBV DNA | ND | ND | ND | N | ND | N | ND | ND |
| Anti-HCV | N | N | N | N | N | N | N | N |
| HEV IgM | N | ND | Ν | N | N | N | N | N |
| HEV RNA | N | N | Detected | N | N | N | N | N |
| HIV | N | N | Ν | N | N | ND | ND | N |
| EBV VCA IgM | N | N | Ν | N | ND | N | N | N |
| EBV DNA | <100 IU/mL | <100 IU/mL | Ν | N | <100 IU/mL | N | N | N |
| CMV IgM | N | N | ND | ND | ND | N | N | N |
| CMV DNA / CMV | N | N | N | N | N | N | N | N |
| pp65 Ag | | | | | | | | |
| HHV-6 DNA | N | N | Ν | N | N | N | N | N |
| HHV-7 DNA | N | N | Ν | N | N | N | N | N |
| Adenovirus DNA | N | N | Ν | N | N | N | N | N |
| Enterovirus RNA | N | N | Ν | N | N | N | N | N |
| ANA | N | N | ND | N | N | N | ND | ND |
| Anti-mitochondrial | N | N | ND | N | N | N | ND | ND |
| Ab | | | | | | | | |
| ANCA | N | N | ND | N | N | ND | ND | ND |
| | | | | | | | | |
| Ultrasound imaging | Normal liver. | Normal | ND | Normal liver | Mildly coarsened | Normal liver | Dilated common | No gross |
| | Non-specific | liver. Biliary | | echotexture. No | parenchymal | Gallstone, no | bile duct and | intrahepatic |
| | hypoenhancing | ducts are | | intrahepatic duct | echogenicity | gallbladder wall | intrahepatic ducts | lesions. |
| | lesions in both liver | not dilated. | | dilatation | Biliary ducts are | thickening. | with intraductal | Intrahepatic ducts |
| | lobes | | | | not dilated. | | stone in distal | are not dilated. |
| | | | | | | | common bile duct. | |
| Liver biopsy | | ND | ND | ND | | ND | ND | |

Appendix Table 7. Investigations in patients with human circovirus infection, Hong Kong Special Administrative Region, People's Republic of China*

*CMV, cytomegalovirus; EBV, Epstein-Barr virus; HHV-6, human herpesvirus 6; HHV-7, human herpesvirus 7; N, not detected; ND, not done; P, detected.

Appendix Table 8. Human circovirus (HCirV) and TT virus loads in peripheral blood of HCirV-infected patients, Hong Kong Special Administrative Region, People's Republic of China. Days of sample collection follows that depicted by + in Figure 2 of the main manuscript.

| Patient | HCirV load (log copies/ml) | TT virus load (log copies/ml) |
|--------------------|----------------------------|-------------------------------|
| P1 | 5.18 | 6.66 |
| | 5.20 | 6.88 |
| | 4.63 | 6.57 |
| | 4.5 | 5.02 |
| | 3.75 | 4.39 |
| | 4.33 | 5.42 |
| | 5.59 | N/A |
| | 5.43 | N/A |
| | 5.21 | N/A |
| | 5.32 | 8.37 |
| | 4.73 | 8.27 |
| P2 | 3.78 | N/A |
| | 3.49 | N/A |
| | 3.48 | N/A |
| P3 | 5.04 | 0 |
| P4 | 5.59 | N/A |
| | 4.02 | 0 |
| | 3.83 | N/A |
| | 3.90 | N/A |
| P5 | 4.89 | N/A |
| | 3.71 | 3.86 |
| P6 | 4.86 | N/A |
| | 3.44 | 5.32 |
| P7 | 3.51 | 5.71 |
| | 3.82 | N/A |
| P8 | 2.78 | 3.62 |
| | 4.13 | N/A |
| | 2.78 | 5.03 |
| N/A: not available | | |

Appendix Table 9. Genome positions of available sequences from HCirV patients, Hong Kong Special Administrative Region, People's Republic of China. Genome positions labeled with reference to ON677309.1. Patient numbering as per Table 2.

| Patient no. | Genome position (bp) |
|-------------|----------------------|
| P1 | 1–2021 |
| P2 | 300–396 |
| P3 | 276–417 |
| P4 | 14–879 |
| P5 | 146–387 |
| P6 | 276–421 |
| P7 | 65–388 |
| P8 | 25–722 |



Appendix Figure 1. Linear regression of the *Rep* gene real-time PCR assay using a dilution series of the plasmid containing the HCirV1 *Rep* gene fragment.



Appendix Figure 2. Immunohistochemical staining of liver tissue from (A) patient 5 and (B) patient 8.



Appendix Figure 3. (A) SDS-PAGE of HCirV Cap protein. (B) Transmission electron microscope image of HCirV Cap protein showing assembly into VLPs. (C) IgG immunoblot of HCirV PCR negative donor samples: lanes 1 – 9 represent individual donor sera while lane 10 is a pooled donor sample



Appendix Figure 4. Cell binding assay showing binding of human circovirus virus-like particles (VLPs) to Hep-G2 cells and A549 cells. Nuclei are counterstained with DAPI.